Your current location:HomeNewsNews

Icolocomf Launched | Dual-target Colorectal Cancer Detection Kit of Ammunition was Issued of Medical Device Registration Certificate for Class Ⅲ Medical Device.



全球首创 · 燃新上市 | 艾米森双靶标结直肠癌检测试剂盒获批!Icolocomf Launched | Dual-target Colorectal Cancer Detection Kit of Ammunition was Issued of Medical Device Registration Certificate for Class Ⅲ Medical Device.





全球首创 · 燃新上市 | 艾米森双靶标结直肠癌检测试剂盒获批!


Complementary dual targets, more significant advantages

01. Early detection of colorectal cancer should focus on the difference between left and right colon
According to the latest statistics from the National Cancer Center, there were 408,000 new cases of colorectal cancer in my country in 2016, and the morbidity and mortality are still on the rise, and it has become the second among all cancers in new cases. The diagnosis rate of early colorectal cancer in my country is less than 10%, which is significantly lower than that of developed countries such as Europe, America, Japan and South Korea. Studies have shown that there are significant differences in epidemiology, pathology, cytogenetics and molecular characteristics between left-sided colon cancer and right-sided colon cancer. To a certain extent, they should be regarded as two different diseases. This difference should be paid more attention to in the detection of early colorectal cancer.

02. Dual target complementation to improve the detection sensitivity of left and right colon cancer
Aichangkang® is the world's first SDC2/TFPI2 dual-target colorectal cancer stool DNA methylation detection product. The product is designed for the difference between the left and right colons. SDC2 methylation is more sensitive to right colon tumors. TFPI2 gene methylation The sensitivity of chemotherapy for left colon tumors is higher, and the combined detection of the two targets can comprehensively increase the detection sensitivity of left and right colon cancers to 95.3%, avoiding missed diagnosis, while maintaining high specificity (93.5%), and improving the detection of advanced adenocarcinoma. The tumor detection sensitivity increased to 63.4%.

03. Single 4.5 hours, single machine 96 samples
Aichangkang optimizes many key steps such as sample pretreatment, nucleic acid extraction, nucleic acid conversion, PCR detection, and process automation. A single sample detection can be completed in 4.5 hours, and a maximum of 96 samples can be processed each time. Aichangkang reduces the sample suspension required for detection to 1.8 ml through patented micro signal enrichment technology (AS-CAP) and ultra-sensitive methylation PCR technology, which requires less laboratory equipment and is more suitable for medical scenarios. Quickly complete high-throughput detection tasks.



全球首创 · 燃新上市 | 艾米森双靶标结直肠癌检测试剂盒获批!


Product performance has been verified by many well-known hospitals

The excellent performance of Aichangkang® dual-target combined detection has been verified by many well-known tertiary hospitals including Peking Union Medical College Hospital, Shanghai Ruijin Hospital, The First Affiliated Hospital of Anhui Medical University, Wuhan University Zhongnan Hospital, etc. The clinical research results are in [Frontiers in Molecular Biosciences], [The Journal of Molecular Diagnostics], [FEBS Open bio], [Cancer Management and Research] and many other international authoritative journals.

全球首创 · 燃新上市 | 艾米森双靶标结直肠癌检测试剂盒获批!

全球首创 · 燃新上市 | 艾米森双靶标结直肠癌检测试剂盒获批!

全球首创 · 燃新上市 | 艾米森双靶标结直肠癌检测试剂盒获批!

全球首创 · 燃新上市 | 艾米森双靶标结直肠癌检测试剂盒获批!








全球首创 · 燃新上市 | 艾米森双靶标结直肠癌检测试剂盒获批!


Multi-party authoritative certification

The product has obtained a number of authoritative certifications from the National Medical Products Administration (NMPA), the European Union and the Ministry of Industry and Information Technology of the People's Republic of China.

全球首创 · 燃新上市 | 艾米森双靶标结直肠癌检测试剂盒获批!全球首创 · 燃新上市 | 艾米森双靶标结直肠癌检测试剂盒获批!






全球首创 · 燃新上市 | 艾米森双靶标结直肠癌检测试剂盒获批!


basic product info
 


1) Product name: SDC2 and TFPI2 gene methylation combined detection kit (fluorescent PCR method).

2) Packaging specifications: 24 tests/box, 48 tests/box, 96 tests/box.

3) Applicable models: LC480, Hongshi, ABI7500

4) Intended use: This product is suitable for auxiliary diagnosis of patients who are recommended by clinicians for colonoscopy.

 

Hotline:17378090801





About Emerson Life Technology

Wuhan Amisen Life Technology Co., Ltd. was established in January 2015. It is a high-tech enterprise focusing on the research and development, registration, production and sales of early non-invasive detection products for high-incidence malignant tumors in the world. The company is committed to the global promotion of cancer early diagnosis technology products. , Combining epigenetics, bioinformatics, clinical big data and artificial intelligence analysis, adhering to the product concept of 'early, accurate, convenient, inclusive', it has created a new generation of tumor screening and detection technology platform and product system, leading the way It has launched a series of early non-invasive detection products covering digestive system tumors, gynecological tumors, urinary system tumors and pan-cancer types, etc., which truly realizes early, non-invasive and accurate detection of tumors, and fundamentally reduces the incidence and death of tumors. rate, nip cancer in the bud, and escort human life and health.

全球首创 · 燃新上市 | 艾米森双靶标结直肠癌检测试剂盒获批!



Early tumor screening to defeat cancer

Emerson Life Technology, keep moving forward!


全球首创 · 燃新上市 | 艾米森双靶标结直肠癌检测试剂盒获批!



share:

Related suggestion